Traders should monitor initiation of the Phase 2 trial and enrollment updates as near-term catalysts; positive data could significantly revalue the stock given the high unmet need and lack of approved therapies in this space.
Price Chart
Executive Summary
Daré Bioscience announced FDA clearance of the IND application for its planned Phase 2 clinical trial of DARE-HPV, a potential treatment for persistent high-risk HPV infection—a condition with no FDA-approved therapy. CEO Sabrina Martucci Johnson discussed the milestone, upcoming trial timelines, and the program’s significance in women’s health, highlighting non-dilutive funding support from ARPA-H.
Key Facts
- FDA cleared the IND application for DARE-HPV, enabling advancement into Phase 2 clinical development.
- DARE-HPV targets persistent high-risk HPV infection, which currently has no FDA-approved drug treatment.
- The company has non-dilutive funding support via an ARPA-H contract to advance development.
- CEO discussed anticipated timelines, risks, and catalysts for the Phase 2 trial in a public investor segment.
- Positive Phase 2 data could position DARE as a first-in-class therapy in cervical disease prevention.
Financial Impact
No immediate financial impact disclosed, but de-risking of DARE-HPV program reduces dilution risk and enhances potential for future partnerships or funding.
Risk Factors
- Phase 2 trial may be delayed or fail to demonstrate efficacy or safety.
- Company remains dependent on raising additional capital; going concern risk persists.
- ARPA-H funding is milestone-dependent and not guaranteed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3254546 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 19d ago | DEF 14A | $0.7900 $0.7720 | ▲ +2.28% | ▲ +1.86% | $0.6467 (+18.14%) |
Oct 1, 2026 25d ago | 8-K | $0.8510 $0.8428 | ▼ −0.96% | ▼ −1.70% | $0.6467 (−24.01%) |
Sep 9, 2026 6w ago | 8-K | $0.7166 $0.7051 | ▼ −1.60% | ▼ −1.01% | $0.6467 (−9.75%) |
Sep 4, 2026 7w ago | EFFECT | $0.7210 $0.7130 | ▲ +1.11% | ▲ +0.56% | $0.6467 (+10.31%) |
Aug 17, 2026 10w ago | 8-K | $0.8102 $0.7682 | ▲ +5.18% | ▲ +4.51% | $0.6467 (+20.18%) |
Aug 17, 2026 10w ago | 424B5 | $0.8102 $0.7682 | ▲ +5.18% | ▲ +4.51% | $0.6467 (+20.18%) |
Aug 13, 2026 10w ago | 8-K | $0.9300 $0.8102 | ▼ −12.88% | ▼ −12.41% | $0.6467 (−30.46%) |
Aug 6, 2026 11w ago | Press Release | $1.33 $1.40 | ▲ +5.26% | ▲ +4.65% | $0.6467 (−51.38%) |
Jul 24, 2026 13w ago | 8-K | $1.28 $1.32 | ▲ +3.13% | ▲ +3.10% | $0.6467 (−49.48%) |
Jul 13, 2026 15w ago | 8-K | $2.09 $2.07 | ▼ −0.96% | ▼ −1.31% | $0.6467 (−69.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers